JP2018529672A5 - - Google Patents

Download PDF

Info

Publication number
JP2018529672A5
JP2018529672A5 JP2018511627A JP2018511627A JP2018529672A5 JP 2018529672 A5 JP2018529672 A5 JP 2018529672A5 JP 2018511627 A JP2018511627 A JP 2018511627A JP 2018511627 A JP2018511627 A JP 2018511627A JP 2018529672 A5 JP2018529672 A5 JP 2018529672A5
Authority
JP
Japan
Prior art keywords
sequence
seq
antibody
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018511627A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529672A (ja
JP6831836B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/050391 external-priority patent/WO2017041092A2/en
Publication of JP2018529672A publication Critical patent/JP2018529672A/ja
Publication of JP2018529672A5 publication Critical patent/JP2018529672A5/ja
Application granted granted Critical
Publication of JP6831836B2 publication Critical patent/JP6831836B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018511627A 2015-09-04 2016-09-06 癌治療のための抗−サバイビン抗体 Active JP6831836B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562214242P 2015-09-04 2015-09-04
US62/214,242 2015-09-04
PCT/US2016/050391 WO2017041092A2 (en) 2015-09-04 2016-09-06 Anti-survivin antibodies for cancer therapy

Publications (3)

Publication Number Publication Date
JP2018529672A JP2018529672A (ja) 2018-10-11
JP2018529672A5 true JP2018529672A5 (enExample) 2019-10-17
JP6831836B2 JP6831836B2 (ja) 2021-02-17

Family

ID=58188638

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018511627A Active JP6831836B2 (ja) 2015-09-04 2016-09-06 癌治療のための抗−サバイビン抗体

Country Status (9)

Country Link
US (3) US10167340B2 (enExample)
EP (1) EP3344287B1 (enExample)
JP (1) JP6831836B2 (enExample)
KR (1) KR102773176B1 (enExample)
CN (1) CN108883163B (enExample)
AU (1) AU2016318158B2 (enExample)
DK (1) DK3344287T3 (enExample)
ES (1) ES2883128T3 (enExample)
WO (1) WO2017041092A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3203732A1 (en) * 2020-12-31 2022-07-07 Health Research, Inc. Anti-survivin antibodies for treatment of autoimmune diseases
US20250018038A1 (en) * 2021-10-06 2025-01-16 The University Of Chicago Survivin targeting polypeptides for detection and treatment of cancer
CN120028549B (zh) * 2023-11-23 2025-11-28 爱威科技股份有限公司 检测丙型肝炎病毒核心蛋白结合蛋白6的试剂盒及应用
CN120025432B (zh) * 2023-11-23 2026-04-21 爱威科技股份有限公司 Hcbp6单克隆抗体及其应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN122080196B (zh) * 2026-04-23 2026-07-24 北京溯本源和生物科技有限公司 一种抗禽流感病毒h7亚型血凝素蛋白的单克隆抗体及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69739105D1 (de) * 1996-11-20 2008-12-24 Univ Yale Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation
JP2003529554A (ja) * 1999-12-21 2003-10-07 エール ユニヴァーシティ サバイビンによる血管形成の促進
CA2499891A1 (en) * 2002-10-03 2004-04-15 Large Scale Biology Corporation Multimeric protein engineering
US7342093B2 (en) * 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
CN101171034B (zh) 2005-03-03 2014-06-18 免疫医疗公司 人源化l243抗体
AU2007230868B2 (en) * 2006-01-13 2012-02-02 Irm Llc Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases
PE20130588A1 (es) 2007-02-02 2013-05-21 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
US8580269B2 (en) 2007-07-19 2013-11-12 Health Research, Inc. Survivin peptides for autoimmune therapies
CA2694011C (en) * 2007-07-19 2016-01-12 Health Research, Inc. Survivin peptides as cancer vaccines
JP5812418B2 (ja) * 2009-04-17 2015-11-11 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
HK1218860A1 (zh) * 2013-02-14 2017-03-17 Immunocellular Therapeutics Ltd. 卵巢癌疫苗及接种方法
CN104098696A (zh) * 2013-04-07 2014-10-15 中美华世通生物医药科技（武汉）有限公司 一种抗血管内皮生长因子的单克隆抗体

Similar Documents

Publication Publication Date Title
RU2016100892A (ru) Антитела против tweakr и их применение
JP2013198490A5 (enExample)
RU2020124153A (ru) Гуманизированные антитела к cd19 человека и способы их применения
FI3487882T3 (fi) Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja
RU2017119543A (ru) Анти-tim3 антитела и способы их применения
JP2019536470A5 (enExample)
RU2016137110A (ru) Антитела к компоненту комплемента с5
JP2020500538A5 (enExample)
JP2014526898A5 (enExample)
JP2017535257A5 (enExample)
JP2010526028A5 (enExample)
JP2022533538A5 (enExample)
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
HRP20240719T1 (hr) Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba
HRP20221088T1 (hr) Protutijela i postupci uporabe
ME02678B (me) Antitijela na ox-40 i postupci njihove primjene
HRP20211444T1 (hr) Anti-dll3 antitijelo
JP2017052784A5 (enExample)
JP2018527919A5 (enExample)
RU2016129517A (ru) Биспецифические антитела к her2 и способы применения
JP2013538057A5 (enExample)
JP2021514973A5 (enExample)
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
JP2020519308A5 (enExample)
JP2015533795A5 (enExample)